and for Stuart, joining this all thank you us morning. Thanks,
of X our for Imagine-X Krabbe disease; of dosing continue committed for in examples progress treatment the approved to options. patient in in progress disorders active dosing transformative no of the Brazil biomarker remain to of trial completion and from of our include; sites X Cohort this mission frontotemporal our of this total clinical Cohort for opening and GALax-C considerable or gangliosidosisl; interim therapies for to additional upliFT-D U.S. first limited We for patient of trial of trial; X in the Imagine-X Recent Cohort current and X of our devastating dementia Cohort the trial sites bringing early make GMX three. positive infantile programs efficacy across developing we as trial dosing CNS our with data clinical safety clinical
Netherlands. in trial active clinical network States, with We of Israel have the UK, programs sites and The global our Canada, established across a sites Brazil, three United
of and an corporate us submitted marks also another the goals metachromatic that disorder. development. X We a in lysosomal storage thrilled leukodystrophy, our a are IND in announce achievement PBMLXX of to having clinical brings rare fourth trial closer for to Phase a This of pediatric program we recently
in our programs needs by elements ongoing to Program Key strategic our and announced our prioritization In decision focus reduce organizational and Therapy FCD. this R&D business support planned we programs continued aligning at forward-looking GMX expenses evaluate mission, As our the disease that for strategy. to and March, our include, more priorities, strategic we continue and to plans accordingly. with clinical advance organization invest programs adapt Krabbe focused our have Gene we of foundational the partnership advancement three of and gangliosidosis, or GTP, continued Penn’s our commitment operating to
exploratory with Focusing disease as Huntington’s for in of epilepsy. as temporal our MLD, preclinical disease, pipeline Alzheimer’s our continued programs well and for investment ALS lobe and programs our research
disease to programs, rights the future programs University in programs two exploratory to our balance three for CNS of retained with adult our rare the Pennsylvania To XA by have a this disease, Parkinson’s prioritization development GTP three result, returned indications. Type Canavan Charcot-Marie-Tooth have external we As in portfolio programs large research adult parties. and for pediatric been or rare and
our quarter well continue our operating into license the made of to multiple This are CNS eight two clinical associated strategic to streamlined and each future reduction a through of clinical across suite. over prioritization productive have pilot review indications Operationally, to on we milestones three partnership additional we next XX% our reductions the PENN’s I and also options We with our via our progress the expenses ongoing years. workforce slowed believe our extends investment retain XXXX, now value-creating for second programs. in manufacturing cash deliver we organization runway positioned will GTP. and
a rapid results by our program, in caused leads severe discuss the disease to neurological GMX several gangliosidosis. PBGMXX and activity gene within most enzyme. lysosomal This GLBX low GMX beta-galactosidase unfortunately, in the to is forms a mortality neurological of storage mutation lead me decline fatal let for First, that years.
four GMX, and forms infantile the I/II trial severe global This escalation Phase the on most enrolling disease. clinical of age dose is early level. an open-label study distinct with which PBGMXX Imagine-X late Our trial of and divided by forms the are cohorts focuses dose
These AAVHUXX GLBX at to in interim from our Symposium report the to magna codon-optimized beta-galactosidase to peripheral administered As next-generation, a Cohort safety and a related tissues. We complications substantially after serum biomarker We pleased efficacy of X events were increased to reminder, in positive and uses clinical on no PBGMXX no based a the delivery. WORLD increase evidence the February. capsid, enzyme and activity showed positive data with data via approach serious conduction enzyme proprietary beta-galactosidase and deliver was and DRG CSF both nerve a delivery. transgene ICM in that studies ICM profile no had cisterna well-tolerated activity safety toxicity brain adverse and demonstrated
very is lysosomal As in we diseases. with we a improvement children have previously for clinical outcome believe discussed, storage milestones important
We’re including the meaningful extremely for in milestones milestones. pleased developmental children see of lost improvement to these regaining
has Our momentum. experienced Imagine-X trial strong on
these and in in Cohort report late patients half have from X. the early the and of infantile dosed now high-dose patient cohorts dosing the remain low-dose on safety XXXX. initial of have both track second each We first We in completed Cohort data the infantile X biomarker of to
Society We week also on American sharing during presentation the oral Cell Annual Wednesday clinical Gene to Therapy look data forward Cohort additional this Meeting. XXth late-breaker and a from during of X
a a Moving on leukodystrophy lysosomal robust results data progression colleagues to is GALax-C. severe the system the cases. marked both mutation years results in key animal recently in a a our Preclinical by Human preclinical journal, Krabbe global storage models Therapy. our disease brain a large ceramidase. Like damaging very decreased published disease Gene GTP this pediatric this in dose-limiting devastating reported disease observed were that in following and biomarkers improvements resulting and called and of in and rapidly, in lysosomal underserved enzyme of and an gene a of PBKRXX progresses caused with progression. life Krabbe fatal neurological toxicities. a GALC of PBKRXX disease program in both activity administration the supporting disease two small These disease Krabbe disease by is that GMX, population condition a galactosyl the single Krabbe expectancy also program is with storage disease only peripheral nervous no with
proprietary address CNS with disease. capsid approach also an and ICM manifestations. open-label patients peripheral study similar, in escalation and the utilizing infantile of to delivery Our PBKRXX is early potentially both Krabbe is GALax-C disease dose same
in opened we dosing announced in first now The In of globally, recruiting the the sites Netherlands, four of Israel. March, Cohort have United trial. clinical States, GALax-C We for and Canada, our including X the patient
and are Grade-X we event. the patient spirit, our all adverse trials, this safety in and with to patient first a that As experienced we share transparency want committed to
Following to review acute this Committee Independent manage event by little the Monitoring in review a brain. procedure and after Grade-X of patient To procedure. of stable XX or study. the has the buildup the with in the dosing, The Data safety hydrocephalus, post a which experienced days been of a proceeding IDMC, underwent data adverse patient condition is a we detail, are CSF the
adverse the the or At of or to this event AAV was blood event cerebral either due of investigation, there spinal to administration evidence the to to the adverse an event, treatment of proximity related an in the be was temporal reaction of or transgene inflammatory Following possibly fluid. study procedures no to time the vector treatment. study assessed
of may the Krabbe progress with baseline a patient. of disease reported showed the and disease role dosing However, association the following be this factor. in the Hydrocephalus of in in has did in also ventricles changes literature the been imaging brain progression evidence that
showed noted biomarker CSF in within psychosine We preliminary of days. GALC normalization serum data also and both rapid reduction that XX of and have activity
of I the to patient As highest safety is importance us. mentioned,
experts the and to development PBKRXX. working been information and have We of advance IDMC external closely with gather to further
of and limit investigators event. The monitoring criteria modifications inclusion and to We has specific of also trial of has These and additional and following of modifications. health safety PBKRXX. changes study administration all with IDMC information this hydrocephalus continuation available clinical the to notified the authorities risk reviewed exclusion potential recommended include
We these expeditiously. are implementing modifications
in are three of per this subjects study event. from four we adverse the following increasing protocol addition, X number In to Cohort
for of patients safety biomarker forward We Cohort the data actively XXXX. reporting and initial and by end are X look recruiting to
GRN the FTD of of clinical is affecting dementia dementia early form that mutation. program, in which FTD devastating is third a a onset is progranulin. seeking treat of with temporal gene frontal to granular our XX. results patients about the to form a disease X% estimated The or between It mutations. Our deficiency by PBFTXX caused of to XX% XX ages is mutation, by with GRN are caused therapy of we granulin is for
treated levels GRN of deficiency the CSF. optional plan The higher different each and to progranulin two than goal We to capsid progranulin ICM with overcome provide observed two CNS the an including to sites, two in We on safety results via now with a cohort ascending area potentially normal the third to this key We United deliver to a three efforts in of of clinical utilizing in Brazil dose, the protein activation biomarker study. to is the cohorts and trial the active continue. first in to approach delivery initial have mutation PBFTXX doses cohorts GRN and higher challenge are depending on enroll the gene Patient at of three AAVX gene a identification two treatment remains focus to the receiving patients carriers. enrolling and and patient sites of continues one additional also our States be
genetic our We on patient mid-XXXX. in FTD continue have the addition are and of be education we free these centers charge in patients referral among expect the to patient to genetic testing recruitment improve testing. to offering will strategies sending additional We of to working trial been closely efforts, testing by to sites kits the clinical with believe opening and dose and trial sites FTD improve rate including employing and clinical first
disease infantile ARSA developmental MLD by the inherited by die is Turning arylsulfatase MLD unfortunately, of in delays lastly to MLD, enzyme A rigidity, disorder a is for which X births. activity. our live reduces age or the by gene, the gait incidence and muscle typically XX,XXX children fatal program in five. Worldwide characterized is leukodystrophy approximately weakness, or caused and metachromatic mutations
MLD, excited have of FDA accomplish I/II for an we to out are Phase IND trial in set submitted clinical which recently by We mid-XXXX. to a to PBMLXX
this This be hopefully to FDA both in poster clinical data will system at and information address of and colleagues we disease. review, study to capsid express the more our manifestations nervous deliver presented utilize our HU-XX this program Following central peripheral the to supporting Meeting will administration devastating about week. plan provide from ASGCT Preclinical ARSA an program. GTP this ICM a
about more for sharing to in program forward future. look also plans this the clinical our We
of our and capsid GMX, Our storage HU-XX therapies review All MLD affecting disorders by focus utilizes the mission across a and each will delivery. to similarities these highlighted programs. our our to approach developing are the and financials. ICM indications children Krabbe turn and clinical to call lysosomal programs novel for I over that, With three Simona now are proprietary
